Personalis Stock Price, News & Analysis

Personalis has rescheduled its ASCO data highlights conference call to Friday, June 21, 2024, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. The call was initially set for Wednesday, June 19, 2024. Participants can join the call by dialing specific numbers for domestic or international access. Additionally, the call will be webcast online through the company's investor relations website, with a replay available after the event.

Personalis announced at ASCO that their NeXT Personal test showed exceptional performance in early-stage breast cancer recurrence detection and immunotherapy monitoring. The test, an ultra-sensitive liquid biopsy, can detect circulating tumor DNA (ctDNA) down to less than 100 parts per million. Results indicated a ~15-month lead time over traditional imaging methods in detecting recurrence, with 100% accuracy in identifying recurrence and cancer-free states. Additionally, for HER2+ breast cancer, NeXT Personal demonstrated a 92% baseline sensitivity for ctDNA. For immunotherapy monitoring, significant decreases in ctDNA levels corresponded to more than double the overall survival rates. These findings suggest strong potential for NeXT Personal in clinical adoption and reimbursement.

Personalis announced a new partnership with Tempus to commercialize NeXT Personal®, their advanced liquid biopsy test used for detecting minimal residual disease (MRD) and cancer recurrence. Tempus' commercial team will start discussions with doctors regarding the test's application in breast and lung cancers, as well as immunotherapy monitoring across all solid tumors. This collaboration aims to enhance cancer patient care by enabling earlier detection and informed treatment decisions. NeXT Personal Dx, launched last October, boasts ultra-sensitive detection capabilities, identifying up to 1,800 unique somatic variants. The test's new data will be presented at the 2024 ASCO Annual Meeting in breast cancer and immunotherapy monitoring.

Personalis announced that two podium presentations and multiple posters featuring its NeXT Personal® ctDNA assay will be showcased at the 2024 ASCO Annual Meeting, set for May 31-June 4 in Chicago. The presentations include studies on ctDNA's role in breast cancer and immunotherapy biomarkers. Dr. Richard Chen highlighted the importance of their ultra-sensitive MRD test in early cancer detection. Key presentations will focus on ctDNA mutation tracking in early breast cancer (Abstract 1010) and ctDNA monitoring in metastatic pan-cancer with immune checkpoint inhibitors (Abstract 2510). Additional abstracts discuss ctDNA dynamics in gastroesophageal and colorectal cancers, as well as HER2+ breast cancer.

Personalis, a leader in advanced genomics for precision oncology, announced that its Compensation Committee has granted a non-qualified stock option to purchase 85,000 shares to its new Vice President, Customer Experience.

The grant, made on May 15, 2024, under the 2020 Inducement Plan, is in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $1.43 per share, matching the closing price on the grant date, and vests over four years.

Personalis, Inc. (Nasdaq: PSNL) reported financial results for Q1 2024, with revenue of $19.5 million, raising full-year revenue guidance due to increased pharma testing demand. They published validation for NeXT Personal MRD test, and launched NeXT Personal Dx clinical testing. The CEO highlighted a focus on the Win-in-MRD strategy and strong execution in Q1.